A Neonate with Hyperammonemia and a Normal Plasma Amino Acid Profile
A 4-day-old term male, birth weight 3.2 kg, breastfed, presents with poor feeding and lethargy progressing to obtundation over 12 hours. Vitals: HR 160, RR 55, temp 36.8 C. Ammonia (drawn from a free-flowing peripheral line, transported on ice, run within 30 minutes) is 410 micromol/L. Repeat is 385 micromol/L. Glucose 62 mg/dL, bicarbonate 21 mmol/L, anion gap 12, AST/ALT normal, total bilirubin 9 mg/dL, direct 0.4. Plasma amino acids show citrulline 8 micromol/L (ref 10-45), arginine 22 micromol/L, glutamine 980 micromol/L, alanine 210 micromol/L, and no orotic acid is detectable in urine. Urine organic acids show no specific diagnostic pattern. Plasma acylcarnitine profile is unremarkable. The infant is now somnolent with intermittent hyperventilation.
1. Before committing to a single enzyme diagnosis, what is your immediate management, and how do you weigh the differential among proximal urea cycle disorders, transient hyperammonemia of the newborn, and a non-urea-cycle cause?
Read the worked answer
Immediate management is diagnosis-independent. Stop all protein intake (including breast milk), start 10% dextrose at high rate to suppress catabolism (target glucose ~8-10 mmol/L, watch for hyperglycemia and hyponatremia from free water), and give intravenous L-arginine (typically 200-400 mg/kg loading then infusion) unless arginine is clearly elevated, plus nitrogen scavengers (sodium phenylbutyrate or sodium benzoate; sodium benzoate plus phenylacetate if available). Carnitine is often added. If ammonia is not falling or exceeds roughly 500 micromol/L with encephalopathy, arrange urgent hemodialysis rather than relying on scavengers alone. Do not delay for a definitive diagnosis.
Weighing the differential: The combination of respiratory alkalosis (implied by hyperventilation), normal anion gap, normal glucose, and very high glutamine with low-normal citrulline and low arginine is the classic biochemical signature of a proximal urea cycle defect, most often CPS1 or OTC deficiency. Absent urinary orotic acid argues against OTC but does not exclude it (sampling timing, dilute urine, or a proximal defect). Transient hyperammonemia of the newborn typically presents in the first 24-48 hours in a preterm or larger infant, often with severe ammonia (>1000) and a relatively normal amino acid profile; a 4-day-old term breastfed infant with glutamine 980 is less typical. A non-urea-cycle cause such as organic acidemia or fatty acid oxidation defect is argued against by the normal anion gap, normal organic acids, and unremarkable acylcarnitines, though these should be repeated if the picture evolves.
Key point: treat now, refine later; the amino acid pattern is supportive but not pathognomonic until confirmatory testing.
2. The family asks whether a specific diagnosis can be made today and whether it changes treatment. How do you counsel them, and what confirmatory testing do you order?
Read the worked answer
Counseling: Explain that the immediate treatment (protein restriction, glucose, arginine, scavengers, dialysis if needed) is the same regardless of which specific enzyme is affected, so care is not delayed. A precise diagnosis matters for prognosis, recurrence risk, and for guiding long-term therapy and possible liver transplantation.
Confirmatory testing:
- Plasma amino acids repeated (glutamine, citrulline, arginine, and look for low citrulline/arginine with high glutamine).
- Urine orotic acid repeated on a concentrated sample; a markedly elevated orotic acid points to OTC deficiency, while low/absent orotic acid with low citrulline points proximally (CPS1 or NAGS).
- Plasma ammonia repeated on a properly handled sample.
- Molecular testing of the urea cycle genes (OTC first, then CPS1, ASS1, ASL, NAGS) as a panel or exome; this is the most reliable way to distinguish entities and to identify carriers.
- Consider enzyme assay on liver if molecular testing is uninformative and the diagnosis remains uncertain.
Prognosis and recurrence: Emphasize that a proximal defect can be severe and that early, aggressive ammonia control correlates with neurologic outcome. Recurrence risk depends on the gene: OTC is X-linked (mother may be a carrier; daughters may be affected), whereas CPS1, ASS1, and ASL are autosomal recessive (25% recurrence). Recommend genetic counseling and, once a variant is found, carrier testing and prenatal/preimplantation options.
Caveat: Do not over-interpret a single normal orotic acid or a single amino acid panel; repeat and integrate with clinical course.